参考文献/References:
[1].Kearney PM,Whelton M,Reynolds K,et al. Global burden of hypertension:analysis of worldwide data[J]. Lancet ,2005,365(9455):217-223.
[2].Calhoun DA,Jones D,Textor S,et al. Resistant hypertension:diagnosis,evaluation,and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J]. Circulation,2008,117(25):e510-e526.
[3].Smithwick RH. Hypertensive vascular disease; results of and indications for splanchnicectomy[J].J Chronic Dis,1955,1(5):477-496.
[4].White PD. Severe hypertension; study of one hundred patients with cardiovascular complications; follow-up results in fifty controls and fifty patients subjected to Smithwick’s lumbodorsal sympathectomy ,1941 to 1946[J]. J Am Med Assoc,1956,160(12):1027.
[5].Mcgregor AL. Essential hypertension,a five-year follow-up of operated cases[J]. S Afr Med J ,1952,26(9):157-161.
[6].Schlaich MP,Sobotka PA,Krum H,et al. Renal sympathetic-nerve ablation for uncontrolled hypertension[J]. N Engl J Med ,2009,361(9):932-934.
[7].Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet ,2009,373(9671):1275-1281.
[8].Kandzari DE,Bhatt DL,Sobotka PA,et al. Catheter‐based renal denervation for resistant hypertension:rationale and design of the SYMPLICITY HTN‐3 Trial[J]. Clin Cardiol,2012,35(9):528-535.
[9].Bakris GL,Townsend RR,Liu M,et al. Impact of renal denervation on 24-hour ambulatory blood pressure:results from SYMPLICITY HTN-3[J]. J Am Coll Cardiol ,2014,64(11):1071-1078.
[10].Floras JS. Sympathetic Nervous System Activation in Human Heart Failure[J]. J Am Coll Cardiol ,2009,54(5):375-385.
[11].Arimoto T,Tada H,Igarashi M,et al. High Washout Rate of Iodine-123-Metaiodobenzylguanidine Imaging Predicts the Outcome of Catheter Ablation of Atrial Fibrillation[J]. J Cardiovasc Electrophysiol,2011,22(12):1297-1304.
[12].Mancia G,Bousquet P,Elghozi JL,et al. The sympathetic nervous system and the metabolic syndrome[J]. J Hypertens,2007,25(5):909-920.
[13].Hausberg M,Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure:a role for chemoreflex activation?[J]. J Hypertens,2007,25(1):47.
[14].朱清一,彭文,柴湘平,等. 肾交感神经导管消融术治疗难治性高血压临床研究进展[J]. 介入放射学杂志,2012,21(8):692-695.
[15].Barajas L,Liu L,Powers K. Anatomy of the renal innervation:intrarenal aspects and ganglia of origin[J]. Can J Physiol Pharmacol ,1992,70(5):735-749.
[16].Esler M. The sympathetic system and hypertension[J]. Am J Hypertens,2000,13(6):S99-S105.
[17].Dibona GF. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function[J]. Hypertension ,2000,36(6):1083-1088.
[18].Kirchheim H,Ehmke H,Persson P. Sympathetic modulation of renal hemodynamics,renin release and sodium excretion[J]. Klin Wochenschr ,1989,67(17):858-864.
[19].Arun,Kannan,Raul,et al. Renal sympathetic nervous system and the effects of denervation on renal arteries[J]. World J Cardiol,2014,6(8):814-823.
[20].Krum H,Sobotka P,Mahfoud F,et al. Device-based antihypertensive therapy:therapeutic modulation of the autonomic nervous system.[J]. Circulation ,2011,123(2):209-215.
[21].Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet ,2009,373(9671):1275-1281.
[22].Rippy MK,Zarins D,Barman NC,et al. Catheter-based renal sympathetic denervation:chronic preclinical evidence for renal arte ry safety[J]. Clin Res Cardiol,2011,100(12):1095-1101.
[23].Li H,Yu H,Zeng C,et al. Renal denervation using catheter-based radiofrequency ablation with temperature control:renovascular safety profile and underlying mechanisms in a hypertensive canine model[J]. Clin Exp Hypertens,2015,37(3):207-211.
[24].Investigators SH. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months[J]. Hypertension ,2011,57(5):911-917.
[25].Esler MD,Krum H,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial) :a randomised controlled trial[J]. Lancet ,2010,376(9756):1903-1909.
[26].Esler MD,Krum H,Schlaich M,et al. Renal sympathetic denervation for treatment of drug-resistant hypertension:one-year results from the Symplicity HTN-2 randomized,controlled trial[J]. Circulation,2012,126(25):2976-2982.
[27].Esler MD,B?hm M,Sievert H,et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension :36 month results from the SYMPLICITY HTN-2 randomized clinical trial[J]. Eur Heart J,2014,35(26):1752-1759.
[28].Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med ,2014,60(1):266-266.
[29].蒋雄京,董徽. 经导管射频消融去肾交感神经术治疗难治性高血压:现实与挑战[J]. 中华高血压杂志,2014,22(5):418-420.
[30].Zhang X,Wu N,Yan W,et al. The effects of renal denervation on resistant hypertension patients:a meta-analysis[J]. Blood Press Monit,2016,21(4):206-214.
[31].Qi XY,Cheng B,Li YL,et al. Renal denervation,adjusted drugs,or combined ther apy for resistant hypertension:A meta-regression[J]. Medicine ,2016,95(30):e3939.
[32].Nagaiah K,Venkatesham A,Srinivasa RR,et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension(DENERHTN) :a multicentre,open-label,randomised controlled trial[J]. Lancet ,2015,385(9981):1957-1965.
[33].Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(2):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(2):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(2):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(2):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(2):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(2):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]